anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the field of basic foot bath products, and discloses a herbal plant foot bath composition, a preparation method and application thereof. The composition is prepared by mixing Ganoderma, radix Rhodiolae, radix Angelicae sinensis and rhizoma Dioscoreae, and has effects of nourishing heart, protecting brain and prolonging life. The moringa seed, the American ginseng, the poria cocos and the astragalus root are mixed, so that the Chinese medicinal composition has the effects of strengthening the body resistance and resisting fatigue. Is prepared by mixing safflower, motherwort, suberect spatholobus stem and tuber fleeceflower stem, and has the effects of promoting blood circulation, removing blood stasis, warming uterus and relieving pain. The ginger, the mugwort leaf, the pricklyash peel, the frankincense and the borneol are mixed, so that the Chinese medicinal composition has the effects of improving immunity and improving sleep. Is prepared from Ligusticum wallichii, achyranthes and cyathula root, akebia stem and licorice root through mixing, and has the effects of dispelling wind, dredging collaterals, relaxing tendons and activating blood circulation. The whole prescription focuses on conditioning the body, improving the skin color, promoting circulation, resisting aging, enhancing immunity and improving the quality of life. The preparation method not only can ensure the precipitation of the effective components of the raw materials, but also can ensure the preservation time of the product, and is convenient to use.
The invention provides a process for producing a purified plasminogen activator substance based on the TPA/pro-TPA couple. Pro-TPA yielding cell cultures are cultivated in a suitable culture medium in the absence of enzymes which catalyse the conversion of pro-TPA into TPA or where such enzymes are present in the presence of a suitable inhibitor adapted to inhibit such enzymes. Accord- : ingly the couple is represented in the harvesting liquid by at least 50 to 100% of pro-TPA and can in fact be virtually 100% pro-TPA, any balance being TPA. The harvesting fluid is treated with an affinity reagent comprising an immobilised Kunitz type inhibitor of the type occurring in seeds of Erythrina latissima and other Erythrina species (DE-3) to selectively adsorb the pro-TPA and any TPA in the harvesting fluid, followed by desorption of pro-TPA and optionally TPA. The pro-TPA so recoverable has 1/10 the plasminogen activating properties of TPA. It is convertable into active TPA enzymatically, e.g. by plasmin or by enzymes present in fibrin clots. The pro-TPA has a higher affinity for fibrin and better selectivity than TPA. It is used for the management and prophylaxis of thrombosis and embolism in dosages of pro-TPA/TPA couple which result in less than 50%, e.g. less than 20% of the plasminogen activating activity resulting from up to 15 mg/24 hrs pure TPA.
The invention discloses a Chinese herbal bone-setting ointment and a preparation method thereof. The Chinese herbal bone-setting ointment comprises active components and an accessory material, wherein the active components comprise, by weight, 5 to 15 parts of root bark of Aralia chinensis L., 5 to 15 parts of root bark of Ampelopsis aconitifolia Bunge, 5 to 15 parts of whole herb of Hypericum ascyron L., 3 to 8 parts of Dianthus chinensis L., 3 to 8 parts of root bark of Boehmeria nivea (L.) Gaud., 3 to 8 parts of whole herb of cynoglossum zeylanicum (Vahl) Thunb. Ex Lehm., 3 to 8 parts of Silene fortunei Vis. and 3 to 8 parts of root of Lysimac-hia fortunei Maxim. The above-mentioned herbal medicines are uniformly mixed and then crushed after removal of impurities, the crushed herbal medicines are screened with an 80-mesh sieve, then 5 to 10 parts of fermented glutinous rice is added, and smashing is carried out so as to obtain the ointment which can be directly used. The Chinese herbal bone-setting ointment can promote rapid growth of considerable calluses at a fracture, accelerates healing of the fracture, reduces pain of patients, is capable of promoting blood circulation to remove blood stasis, promoting reunion of fractured bones, eliminating inflammation, relieving pain, abating fever and diminishing swelling and especially exerts a good curative effect on traumatic fracture caused by traumatic injury.
Disclosed herein is a particle delivery system comprising electrospun nanofiber comprised of coaxial fiber with a microfluidic core. Iron-doped apatite nanoparticles (IDANPs) have demonstrated a unique influence over phage killing of bacteria, whereby, IDANP-exposed bacterial cultures experience 2× the bacterial death as controls. IDANPs consist of hydroxyapatite (HA) doped with iron. HA is a mineral known to be biocompatible and analogous to the inorganic constituent of mammalian bone and teeth and has been approved by the Food and Drug Administration (FDA) for many applications in medicine and dentistry. Previous work has shown that for IDANPs to enhance antibacterial activity of phage to the greatest extent, bacterial cultures should be exposed to IDANPs for 1 hr prior to phage introduction. Biocompatible polymer materials which encase IDANPs and/or phage can be used to disseminate IDANPs and/or phage in a controlled manner into a physiological system for treatment of bacterial infection. When components of said materials contain micro- or nano-scale components, high surface-to-volume ratio for treatment delivery is garnered.
Percutaneous coronary intervention (PCI) is the first treatment for myocardial ischemia; however, if left main coronary artery disease, multivessel disease, or complex architecture disable PCI, 10% of patients may need coronary artery bypass grafting (CABG). Abstinence from surgical reperfusion in patients with acute myocardial infarction (AMI) may be justified due to surgery's 50% mortality rate. An intra-aortic balloon pump (IABP) can help patients who have ongoing ischemia and high cardiac enzymes because it changes the way the heart uses oxygen by increasing coronary blood flow and lowering afterload. Some guidelines do not recommend the use of IABP in patients with AMI except for mechanical complications or shock. Nevertheless, it is commonly acknowledged that the specific criteria for employing IABP differ among clinics and are determined by clinical expertise. Patients with AMI who have impaired coronary perfusion and require surgical revascularization can benefit from preoperative intra-aortic balloon pump (IABP) support. This intervention leads to reorganization of coronary perfusion, resulting in a decrease in elevated troponin levels and quicker myocardial recovery.
VOH is a widely used diagnostic method and seems to be getting more into outpatient clinics. Despite its huge contribution to clinical practice, pain during the procedure is an important limiting factor. We aimed to investigate the effect of the trendelenburg lithotomy position to the pain and procedural time.However, there is a scarcity of research on this subject. Therefore, the rationale of the study was to enlighten the gap in the literature regarding the pain score and procedural time during VOH for diagnostic purposes in TL position. In order to gain scientific evidence, a randomized controlled trial was conducted to compare pain score and duration of procedure between the standard lithotomy position and TL position. Also, the convenience for the physician performing the procedure was assessed. To the best of our knowledge, this is the first study in the literature investigating the effect of the position of the patient during the procedure on both time, pain, and the convenience for the physician simultaneously.
Each patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart and follow-up within 3 months of the last treatment session.
Dilution Techniques: Quantitative methods that are used to determine MICs provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure uses a standardized dilution method1 (broth, agar, or microdilution) or equivalent with cefuroxime powder. The MIC values obtained should be interpreted according to the following criteria:

A report of "Susceptible" indicates that the pathogen, if in the blood, is likely to be inhibited by usually achievable concentrations of the antimicrobial compound in blood. A report of "Intermediate" indicates that inhibitory concentrations of the antibiotic may be achieved if high dosage is used or if the infection is confined to tissues or fluids in which high antibiotic concentrations are attained. This category also provides a buffer zone that prevents small, uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that usually achievable concentrations of the antimicrobial compound in the blood are unlikely to be inhibitory and that other therapy should be selected. 

Standardized susceptibility test procedures require the use of laboratory control microorganisms. Standard cefuroxime powder should give the following MIC values:

Diffusion Techniques: Quantitative methods that require measurement of zone diameters provide estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure2 that has been recommended (for use with disks) to test the susceptibility of microorganisms to cefuroxime uses the 30-mcg cefuroxime disk. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for cefuroxime.

Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30-mcg cefuroxime disk should be interpreted according to the following criteria:

Interpretation should be as stated above for results using dilution techniques.

As with standard dilution techniques, diffusion methods require the use of laboratory control microorganisms. The 30-mcg cefuroxime disk provides the following zone diameters in these laboratory test quality control strains:
All participants will receive PAS in three experimental conditions, randomized to the order of condition. Experimental order will be counterbalanced across participants. Order 1 will be: Seated@Rest, Seated@Active, Walking.
FIELD: organic chemistry, biochemistry, medicine. SUBSTANCE: invention relates to group of novel compounds of the formula (I)   or the formula (II)   where: R 1  represents H, lower alkylthio-group or R 1  in common with R 2  form  ; each of R 2  and R 3  represents independently H or lower alkyl; R 4  represents O atom or H 2 ; R 5  represents H, unsubstituted lower alkyl, cyclohexyl-lower alkyl; each of R 6  and R 7  represents independently hydrogen atom, phenyl, naphthyl, -C(O)-NH-CH, R 13 CO 2 R 14  or unsubstituted phenyl where substituent represents halogen atom, lower alkyl, lower alkoxy-group, hydroxy-group or phenyl-lower alkoxy-group; R 8  represents H or lower alkyl; R 9  represents H or lower alkyl; R 12  represents NR 9  or S atom; R 13  represents lower alkylthio-group; R 14  represents H or lower alkyl, or their pharmaceutically acceptable salts with exception for 4,5-bis-(4-methoxyphenyl)-2-(4-thiazolidinyl-carbonylaminomethyl)-thiazole and its hydrochloride. Invention proposes also separate individual compounds of the above described group of compounds, dimeric compounds consisting of two identical compounds (monomers) of the formulas (I) or (II) linked through disulfide bond that is formed by combination of the first R 1  and the second R 1  monomer and their pharmaceutically acceptable salts. Compounds show inhibitory effect with regards to farnesyltransferase activity in human tumor cells and can be used for treatment of patients with tumors or restenosis. Except for, invention proposes methods of inhibition of activity of farnesyltransferase in human tumor cells using compounds of the present invention. EFFECT: valuable medicinal properties of compounds. 28 cl, 1 tbl, 31 ex
This research will be done to observe efficacy, safety, and tolerability of the classic ketogenic diet (CKD) on an outpatient basis without fasting, caloric and fluid restriction in children with and adolescents with intractable epilepsy.

30 children and adolescents with intractable epilepsy based on inclusion and exclusion criteria have been enrolled in the study, Investigators prescribe them classic ketogenic diet. Efficacy of the diet will be assessed through seizure rates, number of anti-epileptic drug used by the patients, and EEG changes. Seizure frequency will be assessed by seizure record diary that is filled out by family of the patients and will be compared with data that will be taken at 1, 3 months after start of the diet. EEG will be taken at baseline and 3 months after start of the diet. Patients will be reviewed at 1, 3 months after start of the diet at outpatient clinic. Intolerances and Complications will be documented at each clinic visits and via telephone calling during clinic visits intervals to evaluate tolerability and safety of the KD. For close monitoring of the complications along with blood tests and urinalysis Investigators will do echocardiography and renal ultrasound at baseline and 3 months after start of the diet. Laboratory values will be assessed at baseline and 3 months after start of the diet. Also, nutritional status and growth of children will be assessed at baseline and 1, 3 months after start of diet.
Facebook users in the area receive ads which include videos of health professionals encouraging them to help their friends to get vaccinated. There is also a link in the ad to a website build by the study team. This website hosts videos which answer common questions about vaccination (the same videos which are directly served to Facebook users in Treatment 1).
PROBLEM TO BE SOLVED: To prepare decompositional medicinal preparations for ingestion, in which Sildenafil has low solubility in the mouth and is virtually tasteless but is efficiently absorbed from the stomach, etc., and useful therapeutics of human sexual dysfunction by including Sildenafil in the form of its free base together with a pharamceutically acceptable carrier. SOLUTION: The preparations are prepared by including Sildenafil in the form of its free base together with a pharamceutically acceptable carrier (pref. apidly decompositional in the mouth). Preferably, the preparation is carried out by blending both of water soluble fusible binding agent [pref. poly(ethylene glycol) or the like] and at least one kind of vehicles (e.g. mannitol or the like) with Sildenafil in the form of its free base by tabletting the mixture, by melting the binder in the tablet and then by solidifying it.
Symptomatic angina in patients with ischaemia and non-obstructed coronary arteries (INOCA) is common and associated with increased morbidity and adverse outcomes. Myocardial ischaemia often arises from coronary microvascular dysfunction (CMD). Current treatments are limited, and novel evidence-based therapies are needed to address this large unmet clinical need. The Coronary Sinus Reducer (CS Reducer) is a new treatment for refractory angina, which creates a focal narrowing in the coronary sinus that increases back pressure and redistributes blood into ischaemic myocardium at the level of the microcirculation. However the precise mechanism remains unknown. This study will be a randomised double-blinded sham-controlled pilot study (REMEDY-PILOT) to confirm acceptability of CS Reducer implantation, demonstrate feasibility to recruit and quantify its effect on myocardial perfusion. A nested mechanistic substudy within REMEDY-PILOT will test the hypothesis that CS Reducer implantation alters measures of invasive coronary microcirculatory physiology as the mechanistic basis for observed changes in quantitative CMR stress perfusion, symptoms and quality of life.
The invention discloses mild cleansing milk which comprises the following components: 10 to 16 parts of amino acid, 2 to 6 parts of transparent fatty acid, 1 to 5 parts of alkali cleaning component, 2 to 4 parts of aloe gel, 1 to 3 parts of menthol, 0.1 to 0.5 parts of preservative, 0.1 to 1 part of sweet-scented osmanthus extract, 2 to 8 parts of natural marine polysaccharide, 5 to 7 parts of humectant, 0.5 to 2 parts of grape seed extract and the balance of deionized water. According to the mild cleansing milk disclosed by the invention, natural plant components are adopted. The mild cleansing milk is fresh in use and has no side effect. Dirt is effectively cleaned. Meanwhile, the water of skin can also be retained. The mild cleansing milk not only has the effect of cleaning the face but also has the function of protecting the skin.
2,4-dinitroaniline (2,4-D), a widely used dye intermediate, is one of the typical pollutants, and its potential health risks and toxicity are still largely unknown. To explore its subchronic oral toxicity, Wistar rats (equal numbers of males and females) were used as test animals, and a 90-day oral dosing experiment was conducted, divided into control group, low-dose group (0.055 mg/kg), medium-dose group (0.22 mg/kg), medium-high dose group (0.89 mg/kg), and high-dose group (3.56 mg/kg). The body weight data, clinical appearance, and drug reactions of each test rat within 90 days of dosing were recorded; morning urine samples were collected four times to test for eight urinary indicators; blood samples were collected to test for nineteen hematological indicators and sixteen biochemical indicators; tissue samples were collected for pathological analysis; moreover, the no-observed-adverse-effect level (NOAEL) was determined, and the benchmark dose method was used to support this determination and provide a statistical estimate of the dose corresponding. The results indicated that the chronic toxicity of 2,4-dinitroaniline showed certain gender differences, with the eyes, liver, and kidneys being the main potential target organs of toxicity. Moreover, the subchronic oral NOAEL for 2,4-dinitroaniline was determined to be 0.22 mg/kg body weight (0.22 mg/kg for males and 0.89 mg/kg for females), and a preliminary calculation of the safe exposure limit for human was 0.136 mg/kg. The research results greatly enriched the safety evaluation data of 2,4-dinitroaniline, contributing to a robust scientific foundation for the development of informed safety regulations and public health precautions.
Attend 3 health education classes weekly (for 12 weeks), with each class lasting approximately 60 minutes. Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
Tubulointerstitial fibrosis associated with chronic kidney disease (CKD) represents a global health care problem. We previously reported that short and dysfunctional telomeres lead to interstitial renal fibrosis; however, the cell-of-origin of kidney fibrosis associated with telomere dysfunction is currently unknown. We induced telomere dysfunction by deleting the Trf1 gene encoding a telomere-binding factor specifically in renal fibroblasts in both short-term and long-term life-long experiments in mice to identify the role of fibroblasts in renal fibrosis. Short-term Trf1 deletion in renal fibroblasts was not sufficient to trigger kidney fibrosis but was sufficient to induce inflammatory responses, ECM deposition, cell cycle arrest, fibrogenesis, and vascular rarefaction. However, long-term persistent deletion of Trf1 in fibroblasts resulted in kidney fibrosis accompanied by an elevated urinary albumin-to-creatinine ratio (uACR) and a decrease in mouse survival. These cellular responses lead to the macrophage-to-myofibroblast transition (MMT), endothelial-to-mesenchymal transition (EndMT), and partial epithelial-to-mesenchymal transition (EMT), ultimately causing kidney fibrosis at the humane endpoint (HEP) when the deletion of Trf1 in fibroblasts is maintained throughout the lifespan of mice. Our findings contribute to a better understanding of the role of dysfunctional telomeres in the onset of the profibrotic alterations that lead to kidney fibrosis.
FIELD: medicine, hematology. SUBSTANCE: method involves the use of cryoprecipitate or blood plasma as raw that can be treated subsequently if necessary with aluminium hydroxide. After cryoprecipitate dissolving at least a single stage of separation is carried out. Alternative aspect of invention is factor VIII-containing fraction that is subjected for inactivation with virus and additional pasteurization procedure preferably. EFFECT: broadened arsenal of agents used for therapy of coagulating blood system damages. 14 cl
This study will study the medical intervention used when bladder cancer patients present with a new or recurrent bladder tumor. Currently when patients report these tumors, they undergo a standard practice called transurethral resection of the bladder tumor (TURBT) in order to determine the stage of the cancer. This intervention, accomplished by looking through the urethra using an endoscope, is both diagnostic and potentially therapeutic. An adequately performed TURBT will provide the pathologist with enough tissue to provide tumor grade and stage information. Currently, TURBT is done using equipment called monopolar electrocautery which is in the form a 90-degree loop electrode. Although usually safe and sufficient, this technique can create technical challenges because it can be difficult to position the loop electrode in a dynamically changing cylindrical space (the bladder). Specifically, especially with larger bladder tumors, intraoperative bleeding can obscure visualization and result in incomplete tumor resection as well as inadequate sampling of the layers of the bladder needed to establish tumor stage. Furthermore, monopolar current can result in stimulation of a nerve (the obturator nerve) during resection of wall tumors, resulting in violent movement of the leg which can cause a potential bladder tear as well as possible (iliac) vessel injury.

Conversely, a technique using bipolar energy, which has been available for many years, has been readily adopted for the surgical treatment of benign prostatic enlargement. The advantages of a bipolar electrical current include the direct return of electrical current to the loop rather than to a grounding pad placed on the patient's skin. This has the theoretical value of limiting the diffusion of electrical current, and therefore heat, to the surrounding tissue. A further refinement on bipolar energy has been the recent introduction of a piece of equipment called the PlasmaKinetic (PK) Button Vaporization electrode, which is currently approved by the Food and Drug Administration (FDA) for this indication. Coupling bipolar energy into the Button electrode would not only harness the benefits of less thermal spread but also would obviate the geometric challenges associated with loop electrodes during resection of bladder tumors. Procedural advantages would potentially include minimal bleeding, good visualization, and a reduction in the occurrence of the obturator reflex and concomitant bladder perforation.

This study is a randomized double-arm trial examining the results of both techniques for bladder cancer TURBT procedures with a minimum of 120 patients at Emory. The purpose of this study is to measure the procedural (intraoperative), short term, as clinically indicated (4-6 weeks), and long-term (3 months) outcomes of TURBT using the PK Button when compared to traditional monopolar loop electrocautery. The goal of the study is to prove equivalence in outcomes between the two techniques.